Glaucoma and its treatment: A review

American Journal of Health-System Pharmacy

Volumn 62, Issue 7, 2005, Pages 691-699

  Lee, David A ^a,b   Higginbotham, Eve J ^c  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Carbonic anhydrase inhibitors; Costs; Glaucoma; Lasers; Miotics; Optic nerve diseases; Parasympathomimetic agents; Pilocarpine; Prostaglandins; Surgery; Sympatholytic agents; Toxicity

Indexed keywords

ACETAZOLAMIDE; ADRENALIN; ADRENALIN BORATE; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ALPHAGAN P; ANTIGLAUCOMA AGENT; APRACLONIDINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BIMATOPROST; BRIMONIDINE; BRINZOLAMIDE; CARBACHOL; CARBONATE DEHYDRATASE INHIBITOR; CARTEOLOL; CHOLINERGIC RECEPTOR STIMULATING AGENT; CHOLINESTERASE INHIBITOR; DEMECARIUM; DIAMOX SEQUELS; DICLOFENAMIDE; DIPIVEFRINE; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; E PILO 1; E PILO 2; E PILO 3; E PILO 4; E PILO 6; ECOTHIOPATE IODIDE; GLYCEROL; ISOSORBIDE; LATANOPROST; LATANOPROST PLUS TIMOLOL MALEATE; LEVOBUNOLOL; MANNITOL; METHAZOLAMIDE; METIPRANOLOL; OCUDOSE; PHOSHOLINE IODIDE; PHYSOSTIGMINE; PHYSOSTIGMINE SALICYLATE; PILAGEN; PILOCARPINE; PROSTAGLANDIN DERIVATIVE; TIMOLOL; TIMOLOL MALEATE; TRAVOPROST; UNINDEXED DRUG; UNOPROSTONE ISOPROPYL ESTER;

ABDOMINAL CRAMP; ACIDOSIS; ADRENOCHROME DEPOSIT; AGRANULOCYTOSIS; ALLERGIC CONJUNCTIVITIS; ALLERGY; ANALGESIA (SENSORY DYSFUNCTION); ANOREXIA; APLASTIC ANEMIA; ASTHMA; BLEEDING; BLINDNESS; BRADYCARDIA; BRONCHOSPASM; CATARACT; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; CONGESTIVE HEART FAILURE; CONJUNCTIVAL HYPEREMIA; CORNEA ANESTHESIA; CORNEA DISEASE; DEPRESSION; DIABETIC KETOACIDOSIS; DIARRHEA; DISEASE CLASSIFICATION; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; ENURESIS; EXTRASYSTOLE; EYE INFLAMMATION; EYE IRRITATION; GLAUCOMA; GLAUCOMA DRAINAGE IMPLANT; GLAUCOMA SURGERY; HEADACHE; HEALTH CARE COST; HEART BLOCK; HEART FAILURE; HERPES SIMPLEX KERATITIS; HUMAN; HYPERTENSION; HYPERTRICHOSIS; HYPOKALEMIA; HYPOTENSION; IMPOTENCE; INFLAMMATION; INTRAOCULAR PRESSURE; IRIS DISEASE; IRIS PIGMENT EPITHELIAL CYST; IRIS PIGMENTATION; LASER SURGERY; LETHARGY; LIBIDO DISORDER; LUNG DISEASE; MALAISE; MIOSIS; MOOD DISORDER; MYDRIASIS; MYOPIA; NAUSEA; NEPHROLITHIASIS; NIGHT BLINDNESS; OPEN ANGLE GLAUCOMA; OPTIC NERVE DISEASE; PARESTHESIA; PIGMENT DISORDER; PRIORITY JOURNAL; PUNCTATE KERATITIS; RESPIRATORY FAILURE; RETINA DETACHMENT; RETINA MACULA CYSTOID EDEMA; RETINA TEAR; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; SOMNOLENCE; STENOSIS; SUBARACHNOID HEMORRHAGE; SUBDURAL HEMATOMA; SYMPTOM; SYNCOPE; THROMBOCYTOPENIA; TRABECULOPLASTY; VISUAL IMPAIRMENT;

EID: 16244380809     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/62.7.691     Document Type: Review

References (38)

1. American Academy of Ophthalmology Quality of Care Committee Glaucoma Panel. Primary open-angle glaucoma. San Francisco: American Academy of Ophthalmology; 1996:2.
2. U.S. Department of Health, Education, and Welfare. Statistics on blindness in the model reporting area, 1969-70. Washington, D.C.: U.S. Government Printing Office, 1973; DHEW publication no. NIH 73-427.
3. Martin MJ, Sommer A, Gold EB et al. Race and primary open-angle glaucoma. Am J Ophthalmol. 1985; 99:383-7.
4. Wilensky JT, Gandhi N, Pan T. Racial influences in open-angle glaucoma. Ann Ophthalmol. 1978; 10:1398-402.
5. Friedman DS, Wolfs RC, O'Colmain BJ et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol. 2004; 122:532-8.
6. Nemesure B, Wu SY, Hennis A et al. Factors related to the 4-year risk of high intraocular pressure: the Barbados Eye Studies. Arch Ophthalmol. 2003; 121:856-62.
7. Hennis A, Wu SY, Nemesure B et al. Hypertension, diabetes, and longitudinal changes in intraocular pressure. Ophthalmology. 2003; 110:908-14.
8. Wilson MR, Hertzmark E, Walker AM et al. A case-control study of risk factors in open-angle glaucoma. Arch Ophthalmol. 1987; 105:1066-71.
9. Wallace J, Lovell HG. Glaucoma and intraocular pressure in Jamaica. Am J Opthalmol. 1969; 67:93-100.
10. Mason RP, Kosoko O, Wilson MR et al. National survey of the prevalence and risk factors of glaucoma in St. Lucia, West Indies. Ophthalmology. 1989; 96:1363-80.
11. Coulehan JL, Helzlsouer KJ, Rogers KD et al. Racial differences in intraocular tension and glaucoma surgery. Am J Epidemiol. 1980; 111:759-68.
12. Frydman JE, Clower JW, Fulghum JE et al. Glaucoma detection in Florida. JAMA. 1966; 198:1237-40.
13. Tielsch JM, Sommer A, Katz J et al. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. JAMA. 1991; 266:369-74.
14. Quigley HA, Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci. 1997; 38:83-91.
15. Leibowitz HM, Krueger DE, Maunder LR et al. The Framingham Eye Study monograph: an ophthalmological and epidemiological study of cataract, glaucoma, diabetic retinopathy, macular degeneration, and visual acuity in a general population of 2631 adults, 1973-1975. Surv Ophthalmol. 1980; 24(suppl):335-610.
16. Higginbotham EJ, Lee DA, eds. Clinical guide to glaucoma management. Woburn, MA: Butterworth Heinemann; 2004:156-70.
17. Klein BE, Klein R, Lee KE. Heritability of risk factors for primary open-angle glaucoma: the Beaver Dam Eye Study. Invest Ophthalmol Vis Sci. 2004; 45:59-62.
18. Wang N, Wu H, Fan Z. Primary angle closure glaucoma in Chinese and Western populations. Chin Med J. 2002; 115:1706-15.
19. Kass MA, Heuer DK, Higginbotham EJ et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002; 120:701-13,829-30.
20. Jou D, Lee DA. Glaucoma medications: first, do no harm. Rev Ophthalmol. 1998; 5:86-95.
21. Jou D, Lee DA. Protect your patients from iatrogenic glaucoma. Rev Ophthalmol. 1999; 6:112-6.
22. Coleman AL, Morrison JC, Callender O. Evaluation of the optic nerve head. In: Higginbotham EJ, Lee DA, eds. Clinical guide to glaucoma management. Woburn, MA: Butterworth Heinernann; 2004:60-89.
23. Whitaker R, Whitaker VB. Angle-closure glaucoma. In: Higginbotham EJ, Lee DA, eds. Clinical guide to glaucoma management. Woburn, MA: Butterworth Heinemann; 2004:156-70.
24. Gaasterland DE. Advanced glaucoma. In: Higginbotham EJ, Lee DA, eds. Clinical guide to glaucoma management. Woburn, MA: Butterworth Heinemann; 2004:171-82.
25. Rockwood EJ. Medical management of glaucoma. In: Higginbotham EJ, Lee DA, eds. Clinical guide to glaucoma management. Woburn, MA: Butterworth Heinemann; 2004:107-22.
26. Al-Aswad LA, Netland PA. Laser treatment in glaucoma. In: Higginbotham EJ, Lee DA, eds. Clinical guide to glaucoma management. Woburn, MA: Butterworth Heinemann; 2004:391-411.
27. Savage JA. Glaucoma filtration surgery: techniques and intraoperative complications. In: Higginbotham EJ, Lee DA, eds. Clinical guide to glaucoma management. Woburn, MA: Butterworth Heinemann; 2004:424-64.
28. Melamed S, Lee DA. Implantation of setons in glaucoma. In: Higginbotham EJ, Lee DA, eds. Clinical guide to glaucoma management. Woburn, MA: Butterworth Heinemann; 2004:473-93.
29. Higginbotham EJ, Gordon MA, Beiser JA et al. The Ocular Hypertension Treatment Study: topical medication delays or prevents primary open-angle glaucoma in African American individuals. Arch Ophthalmol. 2004; 122:813-20.
30. Heijl A, Leske MC, Bengtsson B et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002; 120:1268-79.
31. Leske MC, Heijl A, Hussein M et al. Factors for glaucoma progression and the effect of treatment: the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2003; 121:48-56.
32. The Advanced Glaucoma Intervention Study (AGIS): 4. Comparison of treatment outcomes within race. Seven-year results. Ophthalmology. 1998; 105:1146-64.
33. Young TL, Higginbotham EJ, Zou XL et al. Effects of topical glaucoma drugs on fistulized rabbit conjunctiva. Ophthalmology. 1990; 97:1423-7.
34. Broadway DC, Grierson I, O'Brien C et al. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Arch Ophthalmol. 1994; 112:1446-54.
35. AGIS Investigators The Advanced Glaucoma Intervention Study (AGIS): 11. Risk factors for failure of trabeculectomy and argon laser trabeculoplasty. Am J Ophthalmol. 2002; 134:481-98.
36. Drance S, Anderson DR, Schulzer M et al. Risk factors for progression of visual field abnormalities in normal-tension glaucoma. Am J Ophthalmol. 2001; 131:699-708.
37. Lichter PR, Musch DC, Gillespie BW et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medication or surgery. Ophthalmology. 2001; 108:1943-53.
38. Janz NK, Wren PA, Lichter PR et al. The Collaborative Initial Glaucoma Treatment Study: interim quality of life findings after initial medical or surgical treatment of glaucoma. Ophthalmology. 2001; 108:1954-65.